Norris Medicines Halts Trading April 1 Ahead of FY26 Results

OTHER
Whalesbook Corporate News Logo
AuthorAnanya Iyer|Published at:
Norris Medicines Halts Trading April 1 Ahead of FY26 Results
Overview

Norris Medicines announced it will close its trading window for key personnel starting April 1, 2026. The move complies with SEBI rules to prevent insider trading before the company releases its audited financial results for the fiscal year and quarter ending March 31, 2026.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Trading Window Closure Announced

Norris Medicines will close its trading window on April 1, 2026. This restriction applies to promoters, directors, auditors, and key managerial staff. The window will remain closed until 48 hours after the company announces its audited financial results for the quarter and fiscal year ending March 31, 2026.

Importance of Trading Window Closures

These closures are essential for maintaining market integrity and preventing insider trading. They ensure that all investors receive material information at the same time, promoting fair and transparent stock dealings.

Company Background

Norris Medicines Limited, founded in 1990, is a pharmaceutical manufacturer based in Ankleshwar, Gujarat. The company produces a variety of formulations and injections and also provides contract manufacturing services. Typically, Norris Medicines announces its quarterly results around mid-April for the fourth quarter and the full fiscal year.

Impact on Company Insiders

Designated individuals at Norris Medicines, including promoters and directors, are barred from trading the company's shares during this period. This prevents them from using any non-public, price-sensitive information before the official financial results are released.

Governance Note

While this trading window closure is a standard compliance measure, the company previously faced regulatory scrutiny from SEBI regarding preferential allotments in 2000.

Peer Practices

Pharmaceutical companies like Shilpa Medicare Limited also follow a similar practice, closing their trading windows from April 1st until after their annual financial results are announced, in line with SEBI's Prohibition of Insider Trading Regulations. Other peers, including Natural Capsules Ltd. and Welcure Drugs and Pharmaceuticals Ltd., are also subject to these rules.

Next Steps for Investors

Investors should watch for the date of the Board Meeting that will approve the audited financial results for the quarter and year ended March 31, 2026. The company will announce the board meeting date in due course. The trading window will reopen 48 hours after the results are officially published.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.